It is announced today that the Japanese Ministry of Health, Labor and Welfare (MHLW) has granted the reimbursement of the Cobalt-60 source which is the active component of MultiSource®, starting from April 1, 2012.

It is announced today that the Chinese State Food and Drug Administration (SFDA) has approved its MultiSource® HDR afterloading system for brachytherapy.

IBt Bebig, a subsidiary of Eckert & Ziegler AG (ISIN DE0005659700) and a leading manufacturer of cancer radiation technology has absorbed all the shares in Bavarian SonoTech GmbH, a minor software developer which has specialised in the planning of radiation therapy.

A MultiSource® Co-60 HDR (High Dose Rate) afterloader equipment has been installed in the Vajira Hospital in Bangkok, Thaïland, which represents the 100th medical center in the world that has opted for the temporary brachytherapy solution proposed by IBt Bebig to treat certain types of cancer by internal irradiation.

Our role as a provider of radiation therapy products in the Commonwealth of Independent States (CIS) has been increased via the acquisition of several large-scale contracts.